Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +47.56%
#3 Cysic Cysic +41.67%
#4 Glidr Glidr +36.41%
#5 Walrus Walrus +29.37%
#6 Humanity Humanity +23.38%
#7 Codatta Codatta +16.38%
#8 Enso Enso +16.32%
#9 Tutorial Tutorial +15.81%
#10 Ribbita by Virtuals Ribbita by Virtuals +14.43%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
Quantum Genomics S.A. Quantum Genomics S.A.

Quantum Genomics S.A.

ALQGC
Rank in Stocks #37063
Quantum Genomics S.A., a biopharmaceutical firm established in Paris, France,... Quantum Genomics S.A., a biopharmaceutical firm established in Paris, France, in 2005, focuses on creating treatments for cardiovascular ailments. Its therapeutic approach utilizes the brain aminopeptidase A inhibition (BAPAI) platform, primarily addressing high blood pressure (hypertension) and heart failure. The company's key asset, firibastat, is currently undergoing a crucial Phase III study as a standalone therapy for hypertension and is also in clinical trials for heart failure. Additionally, Quantum Genomics is progressing QGC011 for hypertension in combination therapy, and further developing QGC006 and QGC606 to target both hypertension and heart failure.
Share Price
$0.07600875
Last synced: 2024-11-20
Market Cap
$2.06M
Change (1 day)
-0.51%
Change (1 year)
0.00%
Country
FR
Trade Quantum Genomics S.A. (ALQGC)

Category

Healthcare
P/B ratio for Quantum Genomics S.A. (ALQGC)
P/B ratio as of August 2026 TTM: -2.05
According to Quantum Genomics S.A. latest financial reports and stock price the company's current price-to-book ratio (TTM) is -2.05. At the end of 2023 the company had a P/B ratio of 8.46.
P/B ratio history for Quantum Genomics S.A. from 2009 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
2026 (TTM) -2.05 -0.18%
2024 -2.05 -124.18%
2023 8.46 649.27%
2022 1.13 -90.55%
2021 11.95 194.68%
2020 4.06 -37.21%
2019 6.46 -8.65%
2018 7.07 87.24%
2017 3.78 -35.35%
2016 5.84 -20.06%
2015 7.31 -103.58%
2014 -204.14 1,261.27%
2013 -15.00 -41.14%
2012 -25.48 74.82%
2011 -14.57 70.19%
2010 -8.56 -101.36%
2009 630.17 0.00%
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -409.91%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -404.99%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 -269.14%
BE